NEUREN PHARMACEUTICALS LIMITED (ASX: NEU)
Health care · News and insights
NEU: $22.74 -1.04% · MC: $2.9B
Latest NEU announcements
Announcement Insights
Neuren Raises 2026 Income Guidance as DAYBUE Sales Accelerate and Japan Deal Advances
Neuren raised its 2026 trofinetide income guidance to approximately US$91–93 million from US$53–56 million after DAYBUE sales growth and a US$35 million milestone earned following the German launch. In the third quarter, DAYBUE sales rose 39% year on year to US$140 million and Neuren’s quarterly royalty income increased 51%; its partner also lifted full-year sales guidance. Separately, Acadia agreed to commercialise DAYBUE STIX in Japan, with a regulatory filing planned for 2027 and a potential 2028 launch subject to approval, alongside sales milestones and tiered royalties for Neuren.
Updated 17 Nov 2026, 09:57 AM Sydney time
Sources
Acadia enters DAYBUE STIX distribution agreement in JapanZita Peach to succeed Patrick Davies as Board ChairInitial Director's Interest Notice - Zita PeachFinal Director's Interest Notice - P. DaviesQ3 2026 DAYBUE net sales up 39%, full year guidance upgradedFDA grants Orphan Drug Designation for NNZ-2591 to treat HIEComments
2026-11-17 · Health care
NEU: $22.74 -1.04% · MC: $2.9B
Neuren Pharmaceuticals’ partner Acadia has signed an exclusive agreement with KYORIN Pharmaceutical to commercialise DAYBUE STIX in Japan. Acadia anticipates a regulatory filing in 2027 and a potential launch in 2028, subject to approval; it had previously said it was seeking a distribution partner. Neuren is entitled to US$15 million after the first commercial sale, potential sales milestones of up to US$110 million and tiered royalties.
Updated 2026-11-17 10:35
Sources
Acadia enters DAYBUE STIX distribution agreement in JapanComments
2026-11-12 · Health care
NEU: $23.66 -1.25% · MC: $2.9B
Neuren Pharmaceuticals has appointed Zita Peach as Board Chair, succeeding Patrick Davies, who has held the role since 2020. Peach brings more than 35 years of healthcare leadership, including experience in licensing, acquisitions and commercialisation; her initial director notice reports no relevant share interests, while Davies’ final notice records an indirect interest in Neuren shares.
Updated 2026-11-12 10:34
Sources
Zita Peach to succeed Patrick Davies as Board ChairInitial Director's Interest Notice - Zita PeachFinal Director's Interest Notice - P. DaviesComments
2026-11-05 · Health care
NEU: $23.24 +17.49% · MC: $2.9B
Neuren Pharmaceuticals raised its annual trofinetide income guidance to US$91 million–US$93 million from US$53 million–US$56 million, including a US$35 million milestone earned from the drug’s German launch. Partner Acadia reported quarterly DAYBUE sales rose 39% from a year earlier to US$140 million, while Neuren’s royalties rose 51% to US$16 million. Acadia also raised its annual global sales guidance and plans a Japanese regulatory filing next year, with a potential launch the following year subject to approval.
Updated 2026-11-05 10:37
Sources
Q3 2026 DAYBUE net sales up 39%, full year guidance upgradedComments
2026-11-02 · Health care
NEU: $20.75 +1.92% · MC: $2.9B
The FDA has granted orphan drug designation to Neuren Pharmaceuticals’ NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, a brain injury caused by insufficient oxygen or blood flow around birth. Neuren is conducting an animal safety study required before a clinical trial and plans to submit an application to begin clinical testing in the first half of 2027. The designation provides incentives including potential marketing exclusivity if the drug is approved.
Updated 2026-11-02 11:25
Sources
FDA grants Orphan Drug Designation for NNZ-2591 to treat HIEComments
Comments